Tin tức & Cập nhật
Lọc theo Chuyên ngành:
RNAi agent RG6346 shows promise for treatment of chronic HBV infection
A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.
RNAi agent RG6346 shows promise for treatment of chronic HBV infection
17 Nov 2023
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
15 Nov 2023
Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.
Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
15 Nov 2023
Tezepelumab cuts OCS use in OCS-dependent patients with severe asthma
Patients with severe asthma who were dependent on oral corticosteroid (OCS) were able to reduce their use of maintenance OCS after treatment with the monoclonal antibody tezepelumab, according to findings from the interim analysis of the phase IIIb WAYFINDER trial.
